Stock analysts at Jefferies Group assumed coverage on shares of Ra Pharmaceuticals Inc (NASDAQ:RARX) in a report released on Monday. The firm set a “buy” rating on the stock.

Separately, SunTrust Banks Inc. initiated coverage on Ra Pharmaceuticals in a report on Monday. They set a “buy” rating for the company.

Shares of Ra Pharmaceuticals (NASDAQ:RARX) opened at 13.29 on Monday. The company’s market capitalization is $7.36 million. The stock has a 50 day moving average price of $13.19 and a 200 day moving average price of $13.19. Ra Pharmaceuticals has a 1-year low of $12.33 and a 1-year high of $14.86.

In related news, Director Rajeev M. Shah acquired 161,538 shares of the business’s stock in a transaction on Monday, October 31st. The stock was purchased at an average cost of $13.00 per share, for a total transaction of $2,099,994.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Harry R. Weller acquired 338,462 shares of the business’s stock in a transaction on Monday, October 31st. The shares were bought at an average price of $13.00 per share, with a total value of $4,400,006.00. The disclosure for this purchase can be found here.

About Ra Pharmaceuticals

Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.

5 Day Chart for NASDAQ:RARX

Receive News & Stock Ratings for Ra Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.